Metformin as an Anticancer Agent

Area of Science:

• Pharmacology and Molecular Biology
• Oncology
• Endocrinology

Background:

• Metformin is a primary treatment for type 2 diabetes (T2D), primarily acting by suppressing hepatic gluconeogenesis.
• Beyond glucose control, metformin exhibits pleiotropic effects, including reduced cancer risk and inhibition of tumorigenesis.
• The precise molecular mechanisms underlying metformin's actions, particularly in cancer, are still under investigation.

Purpose of the Study:

• To review recent advances in understanding the molecular mechanisms of metformin relevant to cancer treatment.
• To explore how metformin regulates key cellular pathways like AMPK and mTORC1 in the context of cancer.
• To discuss mechanisms of metformin action that may not rely on electron transport chain inhibition or ATP depletion.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of studies investigating metformin's effects on cellular signaling pathways.
• Synthesis of data on metformin's impact on AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1).

Main Results:

• Metformin's regulation of AMPK and mTORC1 involves multiple mechanisms, not solely dependent on electron transport chain (ETC) inhibition.
• These regulatory pathways are crucial for metformin's anti-cancer effects.
• Recent findings suggest novel therapeutic applications for metformin in oncology.

Conclusions:

• Metformin's molecular mechanisms in cancer treatment are multifaceted and extend beyond its known effects on glucose metabolism.
• Understanding these pathways offers new avenues for utilizing metformin in cancer therapy.
• Further research into metformin's non-glycemic effects is warranted for its application in oncology.